Precision BioSciences, Inc. (NASDAQ:DTIL) is set to announce third quarter earning results on Tuesday 10th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, DTIL to report 3Q20 loss of $ 0.66 per share.
For the full year, analysts anticipate top line of $ 15.92 million, while looking forward to loss of $ 2.33 per share bottom line.
Previous Quarter Performance
Precision BioSciences, Inc. unwinded loss for the second quarter of $ 0.63 per share, from the revenue of $ 1.08 million. The quarterly revenues declined 77.82 percent compared with the same quarter last year. Street analysts expected Precision BioSciences, Inc. to report loss of $ 0.64 per share on revenue of $ 6.09 million for the second quarter. The bottom line results beat street analysts by $ 0.01 or 1.56 percent, at the same time, top line results fell short of analysts by $ 5.01 million or 82.27 percent.
Stock Performance
Shares of Precision BioSciences, Inc. traded up $ 0.57 or 8.43 percent on Monday, reaching $ 7.27 with volume of 602.90 thousand shares. Precision BioSciences, Inc. has traded high as $ 7.50 and has cracked $ 6.92 on the downward trend
According to the previous trading day, closing price of $ 7.27, representing a 50.45 % increase from the 52 week low of $ 4.46 and a 71.65 % decrease over the 52 week high of $ 23.67.
The company has a market capital of $ 380.55 million and is part of the Healthcare sector and Biotechnology industry.
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food.
